Literature DB >> 17261089

Liver fibrosis: cellular mechanisms of progression and resolution.

Neil C Henderson1, John P Iredale.   

Abstract

Liver fibrosis represents a major worldwide health care burden. The last 15 years have seen a rapid growth in our understanding of the pathogenesis of this clinically relevant model of inflammation and repair. This work is likely to inform the design of effective antifibrotic therapies in the near future. In this review, we examine how the innate and adaptive immune response interacts with other key cell types in the liver, such as the myofibroblast, regulating the process of hepatic fibrosis and, where relevant, resolution of fibrosis with remodelling. Emphasis is placed on the increasing knowledge that has been generated by the use of transgenic animals and animals in which specific cell lines have been deleted. Additionally, we review the increasing evidence that, although significant numbers of wound-healing myofibroblasts are derived from the hepatic stellate cell, significant contributions may occur from other cell lineages, including those from distant sites such as bone marrow stem cells.

Entities:  

Mesh:

Year:  2007        PMID: 17261089     DOI: 10.1042/CS20060242

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  82 in total

1.  Current research in hepatic stem-cell function.

Authors:  Neil D Theise
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

3.  Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis.

Authors:  Pradeep Kumar; Tekla Smith; Khalidur Rahman; Jamie E Mells; Natalie E Thorn; Neeraj K Saxena; Frank A Anania
Journal:  FASEB J       Date:  2014-08-25       Impact factor: 5.191

4.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 6.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

Review 7.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

8.  Influencing factors of transient elastography in detecting liver stiffness.

Authors:  Rong Shan; Hong Yin; Wenjuan Yang; Jianzhi Li; Meifang Zhang; Min Zhao; Jiang Shao; Aiguang Wang
Journal:  Exp Ther Med       Date:  2016-08-24       Impact factor: 2.447

Review 9.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

10.  Experimental obstructive cholestasis: the wound-like inflammatory liver response.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jose García-Domínguez; Jose-Ignacio Arias; Manuel Durán; Jaime Arias
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.